Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
142 hedge funds and large institutions have $1.21B invested in Aimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 48 reducing their positions, and 29 closing their positions.
342% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $3.37M
3% less capital invested
Capital invested by funds: $1.25B → $1.21B (-$34.6M)
6% less funds holding
Funds holding: 151 → 142 (-9)
17% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 48
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.1M |
| 2 |
BlackRock
New York
|
+$9.58M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.31M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$5.27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.7M |
| 4 |
AC
Aisling Capital
New York
|
-$7.07M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.03M |
AIMT Hedge Fund Activity: Q3 2018 in Review
142 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2018, worth a combined $1.21B — down 2.8% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of AIMT and 20 opened new positions — a net loss of 9 holders — while 48 trimmed existing stakes and 40 added.
The largest buyer was AllianceBernstein, adding an estimated $11.1M. The largest seller was Point72 Asset Management, cutting an estimated $37M.
- 142 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2018, down from 151 in Q2 2018.
- Funds reported $1.21B of Aimmune Therapeutics stock for Q3 2018, down 2.8% quarter-over-quarter.
- 20 funds opened new Aimmune Therapeutics positions in Q3 2018 and 29 closed out, a net change of -9 holders.
- The largest Aimmune Therapeutics buyer in Q3 2018 was AllianceBernstein, an estimated $11.1M added.
- The largest Aimmune Therapeutics seller in Q3 2018 was Point72 Asset Management, an estimated $37M sold.
Based on aggregated 13F filings for Q3 2018.